|
For Doctors & Healthcare ProfessionalsBarrett's Oesophagus Clinical Results
Since 2002, the HALO360 System has been evaluated in clinical trials. These studies allow the continued development of this procedural technology as well as provide the clinical evidence to support its use for treating Barrett's oesophagus.
- Tightly controlled, uniform ablation of the epithelium
- Clinical evaulations completed for all types of Barrett's tissue:
intestinal metaplasia, low-grade dysplasia, and high-grade dysplasia
- No strictures, perforations or adverse events reported in any clinical study at 6 or 12 month follow-up
- No buried glands in over 4,500 biopsies
- High median biopsy clearance rate of >90%
- Retreatment is possible if required
- Leading-edge technology results in fast, straightforward, consistent treatment
- Well-tolerated outpatient procedure; median procedure time < 28 minutes
360º Ablation - Complete Healing of Dysplastic and Non-Dysplastic Barrett's
Studies show that the following treatment with the HALO360 System, neosquamous cells begin to grow immediately - with complete healing in approximately one month. In areas free of Barrett's and at follow-up, there have been no noted areas of Barrett's regrowth.
|
PRE-PROCEDURE |
FOLLOW UP |
| Intestinal Metaplasia |
 |
 |
| |
|
12 Months |
| Low-grade dysplasia |
 |
 |
| |
|
12 Months |
| High-grade dysplasia |
 |
 |
| |
|
4 Months |
|
Barrett's Disease
|
Barrett's Oesophagus
|
Barrett's Esophagus
|
Barrett's 0esophagus
|
Barrett's Esophagitis
|
|
Barratts Disease
|
Barratts Oesophagus
|
Barretts Esophagus
|
Barretts 0esophagus
|
Oesophageal Cancer
|
|
|
|
